Table 4.
Most commonly reported adverse events
| Variables | EGFR-TKI group (N=31) | Chemotherapy group (N=29) | EGFR-TKIs plus chemotherapy group (N=32) | |||
|---|---|---|---|---|---|---|
| All grades | Grade ≥3 | All grades | Grade ≥3 | All grades | Grade ≥3 | |
| Leukopenia | 1 (3.2) | 0 (0) | 7 (24.1) | 1 (3.4) | 5 (15.6) | 0 (0) |
| Neutropenia | 2 (6.5) | 0 (0) | 9 (31) | 1 (3.4) | 6 (18.7) | 1 (3.1) |
| Anemia | 1 (3.2) | 0 (0) | 11 (37.9) | 1 (3.4) | 12 (37.5) | 1 (3.1) |
| Thrombocytopenia | 0 (0) | 0 (0) | 6 (20.7) | 0 (0) | 4 (12.5) | 0 (0) |
| Rash | 8 (25.8) | 1 (3.2) | 9 (31) | 0 (0) | 9 (28.1) | 1 (3.1) |
| Diarrhea | 10 (32.2) | 1 (3.2) | 6 (20.7) | 0 (0) | 11 (34.3) | 1 (3.1) |
| Nausea | 0 (0) | 0 (0) | 12 (41.4) | 1 (3.4) | 10 (31.2) | 0 (0) |
| Vomiting | 4 (12.9) | 0 (0) | 5 (17.2) | 1 (3.4) | 4 (12.5) | 0 (0) |
| Cough | 6 (19.4) | 0 (0) | 4 (13.8) | 0 (0) | 3 (9.37) | 0 (0) |
| Fatigue | 6 (19.4) | 0 (0) | 8 (27.6) | 0 (0) | 7 (21.8) | 0 (0) |
| Appetite | 5 (16.1) | 0 (0) | 10 (34.5) | 0 (0) | 5 (15.6) | 1 (3.1) |
| Constipation | 1 (3.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Abbreviation: TKI, tyrosine kinase inhibitor.